يحاول ذهب - حر
Indian pharma ushering in new era of affordable medicines
November 27, 2025
|Chronicle Pharmabiz
INDIA has emerged as a hub of cost -effective medicines for not only developing countries, but also for highly regulated markets Like USA, Canada and Europe.
The cost content of medicine prices is determined by countries regulatory agency National Pharmaceutical Pricing Authority (NPPA), international agencies like USFDA, European Medical Agency. It is also greatly influenced by trends in national and international market.
The Indian pharmaceutical Industry is poised for growth from US$ 30 billion to US$ 70 billion at an annual growth rate ~15 per cent. However at least it can reach US$ 55 billion from US$ 30 billion in 2016 by 2020. The trajectories of phenomenal growth for this forecast are identified as market size expansion [domestic and global], competitive edge in pricing, availability of native human resource, tax reforms [GST bill] growth in health insurance sector, increased income, increased govt spending in public health care and investment by private and government in infrastructure.
There are some factors which can act as barriers to this growth rate such as strict implementation of price control in India, penalties and ban of Indian manufacturers by regulatory agencies due to violations and misappropriations of industrial practices, global hostile socio political developments and unprecedented natural calamities in the world.
Growing generics market
India earns 70 per cent of its revenues by generics in regulated markets. This has become possible due to competitive pricing, development of indigenous CROs who are able to develop bioavailability and bioequivalence data of off patented brand in the global market.
There are many Indian multinational pharmaceutical manufacturers who are approved by international regulatory agencies in India. For example, US FDA opened the India office in New Delhi in 2008, to ensure that food and medical products exported from India to the U.S. are safe, are of good quality, and are effective.
هذه القصة من طبعة November 27, 2025 من Chronicle Pharmabiz.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من Chronicle Pharmabiz
Chronicle Pharmabiz
Home-grown CAR-T cell therapies gaining ground
INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.
4 mins
November 27, 2025
Chronicle Pharmabiz
NPPA extends price fixation on orthopaedic implants for 1 year
IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.
1 mins
November 27, 2025
Chronicle Pharmabiz
FICCI envisages it's Smart AAMs to boost healthcare
In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.
1 min
November 27, 2025
Chronicle Pharmabiz
DoP asked to bring policy for affordable drug pricing
THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.
1 mins
November 27, 2025
Chronicle Pharmabiz
Ramaiah emphasises need for bone health and osteoporosis diagnosis
RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.
2 mins
November 27, 2025
Chronicle Pharmabiz
Nathealth calls for action in 2026-27 Union Budget
NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.
1 mins
November 27, 2025
Chronicle Pharmabiz
Hotspots & growth opportunities in biomanufacturing
THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.
3 mins
November 27, 2025
Chronicle Pharmabiz
Omega Hospitals acquires Cytecare Hospitals
Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.
2 mins
November 27, 2025
Chronicle Pharmabiz
Devices sector hails withdrawal of QCOs
THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.
1 min
November 27, 2025
Chronicle Pharmabiz
'There is urgent need for tech-focused regulatory approach for med devices'
THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.
2 mins
November 27, 2025
Listen
Translate
Change font size
